Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 28 Oct 2019 |
| Orion Group Interim Report 1–9/2019 | 23 Oct 2019 |
| 135,000 Orion Corporation A shares converted into B shares | 2 Sept 2019 |
| Orion Corporation: Managers’ transactions – Timo Lappalainen | 22 Jul 2019 |
| Orion Corporation: Managers’ transactions – Timo Lappalainen | 19 Jul 2019 |
| Orion Corporation: Managers’ transactions – Virve Laitinen | 19 Jul 2019 |